EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access

Predicting Immunological Risk for Stage 1 and Stage 2 Diabetes Using a 1-Week CGM Home Test, Nocturnal Glucose Increments, and Standardized Liquid Mixed Meal Breakfasts, with Classification Enhanced by Machine Learning

Eslam Montaser iD, Marc D Breton iD, Sue A Brown, Mark D DeBoer, Boris Kovatchev iD, Leon S Farhy iD

Diabetes Technology & Therapeutics · 2023

DOI: 10.1089/dia.2023.0064 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Diabetes Technology & Therapeutics, 2023. Verfasst von Eslam Montaser und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for Diabetes Technology, School of Medicine, University of Virginia, Charlottesville, Virginia, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Glucose. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Predicting the risk for type 1 diabetes (T1D) is a significant challenge. We use a 1-week continuous glucose monitoring (CGM) home test to characterize differences in glycemia in at-risk healthy individuals based on autoantibody presence and develop a machine-learning technology for CGM-based islet autoantibody classification.

Methods

Sixty healthy relatives of people with T1D with mean ± standard deviation age of 23.7 ± 10.7 years, HbA1c of 5.3% ± 0.3%, and body mass index of 23.8 ± 5.6 kg/m 2 with zero ( n = 21), one ( n = 18), and ≥2 ( n = 21) autoantibodies were enrolled in an National Institutes of Health TrialNet ancillary study. Participants wore a CGM for a week and consumed three standardized liquid mixed meals (SLMM) instead of three breakfasts. Glycemic outcomes were computed from weekly, overnight (12:00–06:00), and post-SLMM CGM traces, compared across groups, and used in four supervised machine-learning autoantibody status classifiers. Classifiers were evaluated through 10-fold cross-validation using the receiver operating characteristic area under the curve (AUC-ROC) to select the best classification model.

Results

Among all computed glycemia metrics, only three were different across the autoantibodies groups: percent time >180 mg/dL (T180) weekly ( P = 0.04), overnight CGM incremental AUC ( P = 0.005), and T180 for 75 min post-SLMM CGM traces ( P = 0.004). Once overnight and post-SLMM features are incorporated in machine-learning classifiers, a linear support vector machine model achieved the best performance of classifying autoantibody positive versus autoantibody negative participants with AUC-ROC ≥0.81.

Conclusion

A new technology combining machine learning with a potentially self-administered 1-week CGM home test can help improve T1D risk detection without the need to visit a hospital or use a medical laboratory.

Trial registration

ClinicalTrials.gov registration no. NCT02663661.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1GlucoseAdolescentAdultHumansYoung AdultAutoantibodiesBlood GlucoseBlood Glucose Self-MonitoringBreakfastMachine LearningMeals

Stichwörter der Autor:innen

Continuous glucose monitoringImmunological riskIslet autoantibodiesMachine learningPrediabetesType 1 diabetes

Substanzen

AutoantibodiesBlood GlucoseGlucose

Autor:innen und Institutionen

  • Center for Diabetes Technology, School of Medicine, University of Virginia, Charlottesville, Virginia, USA.
  • Division of Endocrinology and Metabolism, Department of Medicine, School of Medicine, University of Virginia, Charlottesville, Virginia, USA.
  • Division of Pediatric Endocrinology, Department of Pediatrics, School of Medicine, University of Virginia, Charlottesville, Virginia, USA.

ORCID-Profile: Eslam Montaser, Marc D Breton, Boris Kovatchev, Leon S Farhy

Förderung

  • NIDDK NIH HHS

Zitieren

APA

Montaser, E., Breton, M. D., Brown, S. A., DeBoer, M. D., Kovatchev, B., & Farhy, L. S. (2023). Predicting Immunological Risk for Stage 1 and Stage 2 Diabetes Using a 1-Week CGM Home Test, Nocturnal Glucose Increments, and Standardized Liquid Mixed Meal Breakfasts, with Classification Enhanced by Machine Learning. Diabetes Technology & Therapeutics. https://doi.org/10.1089/dia.2023.0064

Vancouver

Montaser E, Breton MD, Brown SA, DeBoer MD, Kovatchev B, Farhy LS. Predicting Immunological Risk for Stage 1 and Stage 2 Diabetes Using a 1-Week CGM Home Test, Nocturnal Glucose Increments, and Standardized Liquid Mixed Meal Breakfasts, with Classification Enhanced by Machine Learning. Diabetes Technology & Therapeutics. 2023. doi:10.1089/dia.2023.0064

BibTeX
@article{Montaser2023,
  author = {Montaser, Eslam and Breton, Marc D and Brown, Sue A and DeBoer, Mark D and Kovatchev, Boris and Farhy, Leon S},
  title = {Predicting Immunological Risk for Stage 1 and Stage 2 Diabetes Using a 1-Week CGM Home Test, Nocturnal Glucose Increments, and Standardized Liquid Mixed Meal Breakfasts, with Classification Enhanced by Machine Learning},
  journal = {Diabetes Technology & Therapeutics},
  year = {2023},
  doi = {10.1089/dia.2023.0064}
}
Kostenlos starten →